HHS received a list of 100 ways it could better prepare for and respond to public health emergencies such as pandemics.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
Phase 1 and 2 trials reveal inconclusive subjective results for the drug, which opens respiratory passages.
Americans are not happy with the country's response to the COVID-19 pandemic, according to a new survey from Pew Research Center.
Researchers also estimate that vaccines averted 27 million infections and 1.6 million hospitalizations.
The experimental cancer drug sabizabulin slashed all-cause deaths by 55.2% over placebo in high-risk hospitalized COVID-19 patients by 60 days and was tied to fewer adverse events, according to interim results of a randomized, controlled phase 3 trial published yesterday in NEJM Evidence.
BA.4 and BA.5—which now cause more than 70% of US cases—are 4 times more resistant to 3 vaccine doses than BA.2 is, and only 1 of 19 monoclonal antibodies tested showed efficacy against those subvariants.
In global developments, cases rose for the fourth straight week, led by the BA.4 and BA.5 Omicron subvariants.
Pre-Omicron, the leading causes of death were heart disease (20.1%), cancer (17.5%), and COVID-19 (12.2%).
A study in Ontario suggests that, compared with a third dose of mRNA COVID vaccine, a fourth dose improved protection against infection and severe outcomes among long-term care residents during the Omicron wave. The study was published today in The BMJ.
BA.5 now makes up 53.6% of cases, BA.4 makes up 16.5%, and both are highly transmissible.
The odds of having long COVID fell from 48% before vaccines to 16% after a third vaccine dose.
